桥环吗啡啉盐酸盐 | 31560-06-2

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 桥环吗啡啉盐酸盐
• 中文别名: (1S,4S)-2-氧杂-5-氮杂双环[2.2.1]庚烷盐酸盐；桥环吗啉盐酸盐；桥环吗啡啉
• 英文名称: (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane hydrochloride
• 英文别名: (1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptane hydrogen chloride；(1S,4S)-(+)-2-Aza-5-oxabicyclo[2.2.1]heptane hydrochloride；(1S,4S)-2-oxa-5-azoniabicyclo[2.2.1]heptane;chloride
• CAS: 31560-06-2
• 化学式: C₅H₉NO*ClH
• 分子量: 135.594
• InChiKey: ZFOKPFPITUUCJX-FHAQVOQBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.17
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptane, HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (1S,4S)-2-Oxa-5-azabicyclo[2.2.1]heptane, HCl
CAS number: 31560-06-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H9NO.ClH
Molecular weight: 135.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  桥环吗啡啉盐酸盐 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium tungstate (VI) dihydrate 、 双氧水 、 potassium carbonate 、 二正丁胺 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 为溶剂， 反应 107.0h， 生成 1-[3-[[4-[6-amino-5-(difluoromethoxy)-3-pyridyl]-6-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-2-yl]amino]propyl]azepan-2-one
  参考文献：
  名称：

  Development of a Practical and Greener Process for the Dual Leucine Zipper Kinase Inhibitor GDC-0134 Comprising Two S_NAr Reactions, Oxidation and Suzuki Coupling

  摘要：

  DOI：

  10.1021/acs.oprd.1c00389
• 作为产物：
  描述：

  (2S-trans)-2-hydroxymethyl-4-[[(4-methylphenyl)sulfonyl]oxy]-1-pyrrolidinecarboxylic acid, 1,1-dimethylethyl ester 在 盐酸 、 sodium methylate 作用下， 以 甲醇 、 乙醇 、 甲基叔丁基醚 为溶剂， 反应 2.0h， 生成 桥环吗啡啉盐酸盐
  参考文献：
  名称：

  [EN] PROCESS FOR THE PREPARATION OF BIHETEROARYL COMPOUNDS AND CRYSTAL FORMS THEREOF
  [FR] PROCÉDÉ DE PRÉPARATION DE COMPOSÉS BIHÉTÉROARYLE ET LEURS FORMES CRISTALLINES

  摘要：

  提供制备双杂环芳基化合物的工艺，包括双杂环芳基化合物3-(二氟甲氧基)-5-[2-(3,3-二氟吡咯烷-1-基)-6-[(1S,4S)-2-氧杂-5-氮杂双环[2.2.1]庚烷-5-基]嘧啶-4-基]吡啶-2-胺。该工艺具有以下优点：使用相对无毒和廉价的溶剂；减少昂贵的贵金属催化剂的使用；在某些步骤中降低反应温度；使用相对无毒的氧化剂；使用廉价的过渡金属催化剂；降低某些反应物的摩尔比，从而提高工艺效率同时降低成本和废弃物；在某些步骤中显著提高反应物浓度；消除多重色谱纯化步骤的需要；消除使用有机溶剂进行某些萃取步骤的需要；提高产率和纯度。

  公开号：

  WO2022072721A1
• 作为试剂：
  描述：

  甲基磺酰氯 、 N-(4-chlorobenzyl)-6-(hydroxymethyl)-1-methyl-4-oxo-1,4-dihydro-3-quinolinecarboxamide 、 2,4,6-三甲基吡啶 在 4-二甲氨基吡啶 桥环吗啡啉盐酸盐 、 三乙胺 、 水 、 eluent 、 甲醇 、 二氯甲烷 、 CH2Cl2 hexanes 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以to afford 164.0 mg (53%) of the title compound as a white solid的产率得到N-(4-chlorobenzyl)-1-methyl-6-(2-oxa-5-azabicyclo[2.2.1]hept-5-ylmethyl)-4-oxo-1,4-dihydro-3-quinolinecarboxamide
  参考文献：
  名称：

  Quinolinecarboxamides as antiviral agents

  摘要：

  本发明提供了一种I式化合物，其作为抗病毒剂特别是作为针对疱疹病毒家族的药剂使用。

  公开号：

  US06248739B1

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018137593A1

  公开（公告）日：2018-08-02

  Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

  提供了抑制LRRK2激酶活性的新化合物，以及它们的制备方法、含有它们的组合物以及它们在治疗或预防与LRRK2激酶活性相关或以其为特征的疾病中的用途，例如帕金森病、阿尔茨海默病和肌萎缩侧索硬化症（ALS）。
• [EN] IRAK DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION D'IRAK ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2020264499A1

  公开（公告）日：2020-12-30

  The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。这些化合物包括能够结合到IRAK4的IRAK结合基团和诱导降解的基团（DIM）。DIM可以是DTM、一个连接酶结合基团（LBM）或赖氨酸类似物。这些化合物可以作为IRAK蛋白激酶抑制剂，并应用于IRAK介导的疾病。
• Macrocyclic MCL-1 inhibitors and methods of use
  申请人：AbbVie Inc.

  公开号：US20190055264A1

  公开（公告）日：2019-02-21

  The present disclosure provides for compounds of Formula (I) wherein A 2 , A 3 , A 4 , A 6 , A 7 , A 8 , A 15 , R A , R 5 , R 9 , R 10A , R 10B , R 11 , R 12 , R 13 , R 14 , R 16 , W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

  本公开提供了Formula (I)的化合物，其中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y具有规范中定义的任何值，以及其药学上可接受的盐，可用作治疗疾病和病况的药物，包括癌症。还提供了包含Formula (I)化合物的药物组合物。
• Photoinduced Olefin Diamination with Alkylamines
  作者：Sebastian Govaerts、Lucrezia Angelini、Charlotte Hampton、Laia Malet‐Sanz、Alessandro Ruffoni、Daniele Leonori

  DOI：10.1002/anie.202005652

  日期：2020.8.24

  straightforward approach involves in situ formation and photoinduced activation of N‐chloroamines to give aminium radicals that enable efficient alkene aminochlorination. Owing to the ambiphilic nature of the β‐chloroamines produced, conversion into tetra‐alkyl aziridinium ions was possible, thus enabling diamination by regioselective ring‐opening with primary or secondary amines. This strategy streamlines

  邻二胺是有机化学和药物化学中普遍存在的材料。烯烃和胺的直接偶联将是构建这些基序的理想方法。然而，烯烃二胺化仍然是有机合成中长期存在的挑战，特别是在使用两种不同的胺组分时。我们报告了使用现成的烯烃和胺结构单元直接选择性组装邻位 1,2-二胺的一般策略。这种温和而直接的方法涉及 N-氯胺的原位形成和光诱导活化，产生胺自由基，从而实现有效的烯烃氨基氯化。由于所产生的β-氯胺的两亲性质，可以转化为四烷基氮丙​​啶鎓离子，从而能够通过伯胺或仲胺的区域选择性开环进行二胺化。该策略简化了邻二胺的制备过程，从多步序列简化为单一化学转化。
• C-17 BICYCLIC AMINES OF TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20130296554A1

  公开（公告）日：2013-11-07

  Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 bicyclic amines of triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.

  具有药物和生物活性的化合物、其药物组合物及其使用方法在此予以说明。特别是，提供了具有独特抗病毒活性的C-17双环胺三萜类化合物，作为HIV成熟抑制剂，由公式I、II和III所示的化合物代表：这些化合物可用于治疗HIV和艾滋病。